GlassScriptPhysician profile
Priya Patel
NPI 1770833998
$4,263.89
in general payments reported to CMS, 2019-2025
26 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $610 · 2023: $770 · 2024: $1,170 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $955.91 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $708.32 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $297.07 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Abbvie INC. | $233.58 | 2021-2025 | |
| Exact Sciences Corporation | $223.68 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $212.15 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $197.55 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.39 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $187.42 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.47 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $133.23 | 2024-2025 | Voquezna |
| Amgen INC. | $121.87 | 2021-2024 | Prolia, Evenity |
| Shield Therapeutics INC | $98.44 | 2024-2025 | |
| Lundbeck LLC | $77.16 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $67.18 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $56.89 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $55.86 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Amarin Pharma, INC. | $39.75 | 2022 | |
| Insulet Corporation | $39.17 | 2025 | Omnipod |
| Seagen INC. | $39.02 | 2023 | Adcetris |
| Sanofi-Aventis U.S. LLC | $33.97 | 2022 | |
| Sun Pharmaceutical Industries INC. | $25.44 | 2021 | |
| Phadia US INC. | $25.21 | 2025 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $21.62 | 2023 | Rexulti |
| Medtronic, INC. | $21.55 | 2023 | Inpen Smart Insulin Delivery System |
| Cequr Corporation | $12.99 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.